• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌和前列腺癌中的衰老和骨质疏松症。

Aging and osteoporosis in breast and prostate cancer.

机构信息

Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.

出版信息

CA Cancer J Clin. 2011 May-Jun;61(3):139-56. doi: 10.3322/caac.20103. Epub 2011 May 4.

DOI:10.3322/caac.20103
PMID:21543824
Abstract

As people with cancer survive longer, and as the US population ages, skeletal effects of cancer treatment are becoming more pronounced. This is particularly true for breast and prostate cancer survivors because of the high average age of patients with these malignancies, the propensity of older adults in general toward the development of osteoporosis, and the wide use of therapeutic agents in these cancers that negatively impact bone health. Various therapies used in the treatment and prevention of cancer may cause decreases in bone mineral density and an increased risk of debilitating fracture, even in the absence of bone metastases. Aging is both a baseline risk factor in the development of osteoporosis and bony fracture, as well as a predictor of poor outcome after fracture. A variety of mechanisms may be responsible for the development of bone loss in patients with breast or prostate cancer. Cytotoxic chemotherapy may directly exert long-term toxic effects on bone. Chemotherapy and endocrine therapy can induce hypogonadism, leading to an increased rate of bone loss. The risk of skeletal events in older adults due to cancer therapy should be appreciated by all oncologists, geriatricians, and internists. The following review may serve as a guide to the skeletal side effects of cancer therapy in older adults with breast or prostate cancer, how to screen for treatment-related bone loss, and how to best prevent and/or treat skeletal events.

摘要

随着癌症患者生存期的延长,以及美国人口的老龄化,癌症治疗对骨骼的影响变得更加明显。对于乳腺癌和前列腺癌幸存者来说尤其如此,因为这些恶性肿瘤患者的平均年龄较高,一般老年人更容易发生骨质疏松症,以及这些癌症中广泛使用的对骨骼健康有负面影响的治疗药物。各种用于治疗和预防癌症的疗法可能导致骨矿物质密度降低,并增加致残性骨折的风险,即使没有骨转移也是如此。衰老既是骨质疏松症和骨骨折发生的基线风险因素,也是骨折后不良预后的预测因素。多种机制可能导致乳腺癌或前列腺癌患者发生骨丢失。细胞毒性化疗可能直接对骨骼产生长期毒性作用。化疗和内分泌治疗可诱发性腺功能减退,导致骨丢失率增加。所有肿瘤学家、老年病学家和内科医生都应该认识到癌症治疗对老年人骨骼事件的风险。以下综述可作为乳腺癌或前列腺癌老年患者癌症治疗相关骨骼副作用、如何筛查与治疗相关的骨丢失以及如何最好地预防和/或治疗骨骼事件的指南。

相似文献

1
Aging and osteoporosis in breast and prostate cancer.乳腺癌和前列腺癌中的衰老和骨质疏松症。
CA Cancer J Clin. 2011 May-Jun;61(3):139-56. doi: 10.3322/caac.20103. Epub 2011 May 4.
2
Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.了解前列腺癌患者骨质流失和骨转移的治疗方法:临床医生实用综述与指南
Urol Clin North Am. 2004 May;31(2):331-52. doi: 10.1016/j.ucl.2004.01.001.
3
Androgen deprivation in veterans with prostate cancer: implications for skeletal health.前列腺癌退伍军人的雄激素剥夺:对骨骼健康的影响。
Ann Pharmacother. 2006 Dec;40(12):2107-14. doi: 10.1345/aph.1H209. Epub 2006 Nov 28.
4
Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer.预防接受乳腺癌化疗的女性骨矿物质密度流失的干预措施。
Clin J Oncol Nurs. 2005 Apr;9(2):177-84. doi: 10.1188/05.CJON.177-184.
5
Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer.
Oncol Nurs Forum. 2007 Jan;34(1):55-63. doi: 10.1188/07.ONF.55-36.
6
Cancer treatment-induced bone loss.癌症治疗引起的骨质流失。
Curr Opin Endocrinol Diabetes Obes. 2007 Dec;14(6):442-5. doi: 10.1097/MED.0b013e3282f169b5.
7
Cancer treatment-induced bone loss in breast and prostate cancer.乳腺癌和前列腺癌中癌症治疗引起的骨质流失。
J Clin Oncol. 2008 Nov 20;26(33):5465-76. doi: 10.1200/JCO.2008.18.4184. Epub 2008 Oct 27.
8
Adverse bone effects during pharmacological breast cancer therapy.乳腺癌药物治疗期间的不良骨骼影响。
Acta Oncol. 2008;47(4):747-54. doi: 10.1080/02841860802001467.
9
Early breast and prostate cancer and clinical outcomes (fracture).早期乳腺癌和前列腺癌及临床结局(骨折)。
Oncology (Williston Park). 2009 Dec;23(14 Suppl 5):16-20.
10
Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma.化疗对睾丸癌和淋巴瘤男性幸存者骨骼健康的影响。
Clin Cancer Res. 2006 Nov 1;12(21):6480-6. doi: 10.1158/1078-0432.CCR-06-1382.

引用本文的文献

1
Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for osteoporosis.全基因组可药物作用靶点的系统性孟德尔随机化研究确定了骨质疏松症的治疗靶点。
Osteoporos Sarcopenia. 2025 Jun;11(2):57-64. doi: 10.1016/j.afos.2025.06.001. Epub 2025 Jun 7.
2
Association between depression and osteoporosis in a population of cancer survivors: results from the NHANES 2005-2020.癌症幸存者群体中抑郁症与骨质疏松症的关联:2005 - 2020年美国国家健康与营养检查调查结果
Front Med (Lausanne). 2025 Apr 22;12:1515435. doi: 10.3389/fmed.2025.1515435. eCollection 2025.
3
Subsequent primary cancer risk and mortality among premenopausal breast cancer survivors.
绝经前乳腺癌幸存者后续发生原发性癌症的风险及死亡率
Sci Rep. 2025 Mar 28;15(1):10829. doi: 10.1038/s41598-024-84606-7.
4
[Determinants in the quality of life of breast cancer survivors].[乳腺癌幸存者生活质量的决定因素]
Aten Primaria. 2025 Mar 17;57(9):103253. doi: 10.1016/j.aprim.2025.103253.
5
Epigenetic Landscapes of Aging in Breast Cancer Survivors: Unraveling the Impact of Therapeutic Interventions-A Scoping Review.乳腺癌幸存者衰老的表观遗传景观:揭示治疗干预的影响——一项范围综述
Cancers (Basel). 2025 Mar 3;17(5):866. doi: 10.3390/cancers17050866.
6
Unveiling the Link Between Breast Cancer Treatment and Osteoporosis: Implications for Anticancer Therapy and Bone Health.揭示乳腺癌治疗与骨质疏松症之间的关联:对癌症治疗和骨骼健康的影响。
Biomed Res Int. 2024 Nov 14;2024:5594542. doi: 10.1155/2024/5594542. eCollection 2024.
7
Single-cell analysis reveals alternations between the aged and young mice prostates.单细胞分析揭示了老年和年轻小鼠前列腺之间的差异。
Biomark Res. 2024 Oct 9;12(1):117. doi: 10.1186/s40364-024-00666-x.
8
Traditional Chinese medicine in osteoporosis: from pathogenesis to potential activity.中医在骨质疏松症中的应用:从发病机制到潜在活性
Front Pharmacol. 2024 Apr 2;15:1370900. doi: 10.3389/fphar.2024.1370900. eCollection 2024.
9
Comprehensive Characterization of Ageing-Relevant Subtypes Associated With Different Tumorigenesis and Tumor Microenvironment in Prostate Cancer.前列腺癌中与不同肿瘤发生和肿瘤微环境相关的衰老相关亚型的综合表征
Front Mol Biosci. 2022 Feb 21;9:803474. doi: 10.3389/fmolb.2022.803474. eCollection 2022.
10
miR-29cb2 promotes angiogenesis and osteogenesis by inhibiting HIF-3α in bone.微小RNA-29cb2通过抑制骨中的低氧诱导因子-3α促进血管生成和成骨作用。
iScience. 2021 Dec 10;25(1):103604. doi: 10.1016/j.isci.2021.103604. eCollection 2022 Jan 21.